[1] PISCHON T,BOEING H,HOFFMANN K,et al. General and abdominal adiposity and risk of death in Europe[J]. N Engl J Med,2008,359(20):2105-2120. [2] CHITTURI S,FARRELL GC. Fatty liver now,diabetes and heart attack later. The liver as a barometer of metabolic health[J]. J Gastroenterol Hepatol,2007,22(7):967-969. [3] FAN JG,Li F,CAI XB,et al. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders[J]. J Gastroenterol Hepatol,2007,22(7):1086-1091. [4] TARGHER G,BERTOLINI L,PADOVANI R,et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease[J]. Diabetes Care,2006,29(6):1325-1330.
[5] HANLEY AJ,WILLIAMS K,FESTA A,et al. Elevations in markers of liver injury and risk of type 2 diabetes:the insulin resistance atherosclerosis study[J]. Diabetes,2004,53(10):2623-2632. [6] LUO B,WANG Y,WANG K. Association of metabolic syndrome and hepatitis B infection in a Chinese population[J].Clin Chim Acta,2007,380(1-2):238-240. [7] JAN CF,CHEN CJ,CHIU YH,et al. Apopulation-based study investigating the association between metabolic syndrome and hepatitis B/C infection(Keelung Community-based Integrated Screening study No.10)[J]. Int J Obes(Lond),2006,30:794-749. [8] WONG GL,WONG VW,CHOI PC,et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B[J]. Gut,2009,58(1):111-117. [9] CZAJA AJ,CARPENTER HA,SANTRACH PJ,et al. Host- and disease-specific factors affecting steatosis in chronic hepatitis C[J]. J Hepatol,1998,29(2):198-206. [10] ALTLPARMAK E,KOKLU S,YALINKILIC M,et al. Viral and host causes of fatty liver in chronic hepatitis B[J]. World J Gastroenterol,2005,11(20):3056-3059. [11] GORDON A,MCLEAN CA,PEDERSEN JS,et al. Hepatic steatosis in chronic hepatitis B and C: predictors,distribution and effect on fibrosis[J]. J Hepatol,2005,43(1):38-44. [12] THOMOPOULOS KC,ARVANITI V,TSAMANTAS AC,et al. Prevalence of liver steatosis in patients with chronic hepatitis B:a study of associated factors and of relationship with fibrosis[J]. Eur J Gastroenterol Hepatol,2006,18(3):233-237. [13] BONDINI S,KALLMAN J,WHEELER A,et al. Impact of non-alcoholic fatty liver disease on chronic hepatitis B[J]. Liver Int,2007,27(5):607-611. [14] CINDORUK M,KARAKAN T,UNAL S. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection[J]. J Clin Gastroenterol,2007,41(5):513-517. [15] TSOCHATZIS E,PAPATHEODORIDIS GV,MANESIS EK,et al. Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors:a comparative approach with genotype 1 chronic hepatitis C[J]. Dig Liver Dis,2007,39(10):936-942. [16] CHU CM,LIN DY,LIAW YF. Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus(HBV)surface antigen in chronic HBV infection[J]. Int J Obes(Lond),2007,31(5):871-875. [17] WANG CC,HSU CS,LIU CJ,et al. Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis[J]. J Gastroenterol Hepatol,2008,23(5):779-782.[18] SHI JP,FAN JG,WU R,et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection[J]. J Gastroenterol Hepatol,2008,23(9):1419-1425. [19] PENG D,HAN Y,DING H,et al. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors[J]. J Gastroenterol Hepatol,2008,23(7 Pt 1):1082-1088. [20] YUN JW,CHO YK,PARK JH,et al. Hepatic steatosis and fibrosis in young men with treatment-nave chronic hepatitis B[J]. Liver Int,2009,29(6):878-883. [21] MINAKARI M,MOLAEI M,SHALMANI HM,et al. Liver steatosis in patients with chronic hepatitis B infection:host and viral risk factors[J]. Eur J Gastroenterol Hepatol,2009,21(5):512-516. [22] PERSICO M,MASARONE M,LAMURA V,et al. Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis:differences and similarities[J]. World J Gastroenterol,2009,15(4):462-466 [23] ELLOUMI H,HEFAIEDH R,GARGOURI D,et al. Hepatic steatosis in chronic hepatitis B:contributing factors and effect on fibrosis[J]. Tunis Med,2008,86(11):1000-1003. [24] KUMAR M,CHAUHAN R, GUPTA N,et al. Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients[J]. Gastroenterology,2009;136(4):1272-1280. [25] PARK SH,KIM DJ,LEE HY. Insulin resistance is not associated with histologic severity in nondiabetic,noncirrhotic patients with chronic hepatitis B virus infection[J]. Am J Gastroenterol,2009,104(5):1135-1139. [26] KIM KH,SHIN HJ,KIM K,et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma[J]. Gastroenterology,2007,132(5):1955-1967. [27] NA TY,SHIN YK,ROH KJ,et al. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma[J]. Hepatology,2009,49(4):1122-1131.[28] FARRELL GC,CHITTURI S,LAU GK,et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary[J]. J Gastroenterol Hepatol,2007,22(6):775-777. [29] SHIRATORI Y,YOSHIDA H,OMATA M. Management of hepatocellular carcinoma:advances in diagnosis,treatment and prevention[J]. Expert Rev Anticancer Ther,2001,1(2):277-290. [30] DORE GJ,FREEMAN AJ,LAW M,et al. Is severe liver disease a common outcome for people with chronic hepatitis C[J]. J Gastroenterol Hepatol,2002,17(4):423-430. [31] MEHTA SH,BRANCATI FL,STRATHDEE SA,et al. Hepatitis C virus infection and incident type 2 diabetes[J].Hepatology,2003,38(1):50-56. [32] HUI JM,SUD A,FARRELL GC,et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected] [J]. Gastroenterology,2003,125(6):1695-1704. [33] TAMAKA N,NAGAYA T,KOMATSU M,et al. Insulin resistance and hepatitis C virus:a case-control study of non-obese,non-alcoholic and non-steatotic hepatitis virus carriers with persistently normal serum aminotransferase[J]. Liver Int,2008,28(8):1104-1111. [34] DUSEJA A,DHIMAN RK,CHAWLA Y,et al. Insulin resistance is common in patients with redominantly genotype 3 chronic hepatitis C[J]. Dig Dis Sci,2009,54(8):1778-1782. [35] POUSTCHI H,NEGRO F,HUI J,et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3[J]. J Hepatol,2008,48(1):28-34. [36]CONJEEVARAM HS,KLEINER DE,EVERHART JE,et al. Race,insulin resistance and hepatic steatosis in chronic hepatitis C[J]. Hepatology,2007,45(1):80-87. [37] ZEIN NN,ETANERCEPT STUDY GROUP. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection:a phase 2 randomized, double-blind,placebo-controlled study[J]. J Hepatol,2005,42(3):315-322. [38] ROMERO-GóMEZ M,DEL MAR VILORIA M,ANDRADE RJ,et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients[J]. Gastroenterology,2005,128(3):636-641. [39]TSCCHATZIS EA,MANOLAKOPOULOS S,PAPATHEO-DORDIS GV,et al. Insulin resistance and metabolic syndrome in chronic liver diseases:old entities with new implications[J]. Scand J Gastroenterol, 2009,44(1):6-14. [40] LO IACONO O,VENEZIA G,PETTA S,et al. The impact of insulin resistance,serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C[J]. Aliment Pharmacol Ther,2007,25(10):1181-1191. [41] MANGIA A,MINERVA N,BACCA D,et al. Determinants of relapse after a short(12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection[J]. Hepatology,2009,49(2):358-363. [42] CHU CJ,LEE SD,HUNG TH,et al. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin[J]. Aliment Pharmacol Ther,2009,29(1):46-54. [43] DAI CY,HUANG JF,HSIEH MY,et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients[J]. J Hepatol,2009,50(4):712-718. [44] NASTA P,GATTI F,PUOTI M,et al. Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfected patients on peginterferon-alfa-2a[J]. AIDS,2008,22(7):857-861. [45] ELGOUHARI HM, ZEIN CO,HANOUNEH I,et al. Diabetes Mellitus Is Associated with Impaired Response to Antiviral Therapy in Chronic Hepatitis C Infection[J]. Dig Dis Sci,2009.